Sundia congratulates Betta Pharmaceuticals for X-396 IND approval in China

In August 2016, Betta Pharmaceuticals Co., Ltd. has successfully received X-396 CFDA IND approval in the class 1.1 IND application. The innovative target therapy, X-396, is aim to provide treatments for ALK positive and NSCLC patients that developed progression with crizotinib treatment.

Sundia is honored to have contributed to and assisted in conducting pre-clinical CMC ( synthesis, formulation, and analysis) study as well as facilitating the successful on-site verification by the PFDA.

News Center
Copyright© 2004-2010 Sundia MediTech Company, LTD. All rights reserved   沪ICP备 08100154号